Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
New Diagnostic and Therapeutic Aspects of Thrombotic Thrombocytopenic Purpura

New Diagnostic and Therapeutic Aspects of Thrombotic Thrombocytopenic Purpura

Mancini, Ilaria
Artoni, Andrea

Hardcover

Medical Reference

ISBN10: 3725828598
ISBN13: 9783725828593
Publisher: Mdpi AG
Published: Jan 7 2025
Pages: 142
Weight: 1.14
Height: 0.50 Width: 6.69 Depth: 9.61
Language: English
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy caused by congenital or acquired severe deficiency of the von Willebrand factor cleaving protease, ADAMTS13. Acute TTP is a medical emergency requiring a rapid differential diagnosis and immediate treatment, which is often challenging due to the overlap between clinical and laboratory features and other thrombotic microangiopathies. Diagnostic and therapeutic advancements over the past decade, including the increased availability of ADAMTS13 testing and the development of caplacizumab, the first targeted therapy for acquired TTP, have significantly improved the management of acute TTP and reduced the burden of short-term outcomes such as mortality and exacerbation of acute disease. Concurrently, new clinical challenges have emerged, to mention but one, addressing the burden of long-term complications of TTP and cardiovascular comorbidities in TTP patients in remission.

Also in

Medical Reference

View All